| Symbol | AVTX |
|---|---|
| Name | AVALO THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 540 GAITHER ROAD,SUITE 400, ROCKVILLE, Maryland, 20850, United States |
| Telephone | +1 410 522-8707 |
| Fax | — |
| — | |
| Website | https://www.avalotx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001534120 |
| Description | Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006. Additional info from NASDAQ: |
Sullivan Christopher Ryan 🟡 adjusted position in 72.7K shares (3 derivative) of Avalo Therapeutics, Inc. (AVTX) at $20.05 ($2.9M) Transaction Date: Aug 17, 2026 | Filing ID: 000019
Read moreDoyle Mittie 🟡 adjusted position in 1.0K shares (1 derivative) of Avalo Therapeutics, Inc. (AVTX) at $20.00 Transaction Date: Aug 17, 2026 | Filing ID: 000029
Read more📋 CHRISTOPHER RYAN SULLIVAN (Officer) plans to sell 31K shares of AVALO THERAPEUTICS, INC. (at $20.05 each, total $622K) Filed: Aug 18, 2026 | ID: 008317
Read more📋 MITTIE DOYLE (Officer) plans to sell 5K shares of AVALO THERAPEUTICS, INC. (at $19.59 each, total $99K) Filed: Aug 17, 2026 | ID: 008276
Read more📋 CHRISTOPHER RYAN SULLIVAN (Officer) plans to sell 71K shares of AVALO THERAPEUTICS, INC. (at $19.59 each, total $1.4M) Filed: Aug 17, 2026 | ID: 008273
Read more📋 CHRISTOPHER RYAN SULLIVAN (Officer) plans to sell 4K shares of AVALO THERAPEUTICS, INC. (at $19.94 each, total $75K) Filed: Aug 17, 2026 | ID: 008220
Read moreNew Form SCHEDULE 13G/A - Avalo Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097285 <b>Size:</b> 11 KB
Read moreNew Form SCHEDULE 13G/A - Avalo Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001727492-26-000021 <b>Size:</b> 10 KB
Read moreNew Form SCHEDULE 13G/A - Avalo Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0000921895-26-002164 <b>Size:</b> 25 KB
Read moreNew Form SCHEDULE 13G/A - Avalo Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003475 <b>Size:</b> 11 KB
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06603077 | A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Modera… | Phase2 | Hidradenitis Suppurativa | Completed | 2024-09-16 | 2026-03-17 | ClinicalTrials.gov |
| NCT05288504 | A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Po… | Phase2 | Non-Eosinophilic Asthma | Completed | 2022-02-24 | 2023-05-11 | ClinicalTrials.gov |
| NCT04994002 | A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 i… | Phase1 | Lymphatic Malformation | Withdrawn | 2021-09-03 | 2022-06-01 | ClinicalTrials.gov |
| NCT04671251 | Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Mye… | Phase1 | Multiple Myeloma | Completed | 2020-12-15 | 2022-03-30 | ClinicalTrials.gov |
| NCT03169894 | Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With… | Phase1 | Crohn Disease | Terminated | 2017-07-14 | 2021-10-12 | ClinicalTrials.gov |
| NCT02459236 | A Study of Intermittent Doses of CERC-301 in MDD | Phase2 | Major Depressive Disorder | Completed | 2015-06-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01941043 | A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CE… | Phase2 | Major Depressive Disorder | Completed | 2013-11-01 | 2014-10-01 | ClinicalTrials.gov |
| NCT01703923 | An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough | Phase2 | Chronic Refractory Cough | Completed | 2012-11-01 | 2013-09-01 | ClinicalTrials.gov |
| NCT01597349 | Antitussive Effects of FP01 Lozenges in Subjects With Cough Due to Upper Respir… | Phase2 | Acute Cough | Completed | 2012-05-01 | 2012-09-01 | ClinicalTrials.gov |
| NCT01579526 | A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozeng… | Phase1 | Healthy | Completed | 2012-04-01 | 2012-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| CERC-006 | Other | Phase PHASE1 | Lymphatic Malformation | WITHDRAWN | NCT04994002 |
| FP01 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT01579526 |
| FP01 | Other | Phase PHASE2 | Acute Cough | COMPLETED | NCT01597349 |
| placebo | Other | Phase PHASE2 | Chronic Refractory Cough | COMPLETED | NCT01703923 |
| FP01 | Other | Phase PHASE2 | Chronic Refractory Cough | COMPLETED | NCT01703923 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02459236 |
| CERC-301 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02459236 |
| Placebo | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01941043 |
| CERC-301 | Other | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT01941043 |
| MDGN-002 | Other | Phase PHASE1 | Crohn Disease | TERMINATED | NCT03169894 |
| AEVI-007 | Other | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04671251 |
| Placebo | Other | Phase PHASE2 | Non-Eosinophilic Asthma | COMPLETED | NCT05288504 |
| AVTX-002 | Other | Phase PHASE2 | Non-Eosinophilic Asthma | COMPLETED | NCT05288504 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| Placebo | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 1 | Other | Phase PHASE2 | Hidradenitis Suppurativa | COMPLETED | NCT06603077 |
| AVTX-009 Regimen 2 | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06603077 |
| AVTX-009 Regimen 1 | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06603077 |
| AVTX-002 | DRUG | Phase PHASE2 | Non-Eosinophilic Asthma | COMPLETED | NCT05288504 |
| CERC-006 | DRUG | Phase PHASE1 | Lymphatic Malformation | WITHDRAWN | NCT04994002 |
| AEVI-007 | DRUG | Phase PHASE1 | Multiple Myeloma | COMPLETED | NCT04671251 |
| MDGN-002 | DRUG | Phase PHASE1 | Crohn Disease | TERMINATED | NCT03169894 |
| Placebo | DRUG | Phase PHASE2 | Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | NCT06603077 |
| CERC-301 | DRUG | Phase PHASE2 | Major Depressive Disorder | COMPLETED | NCT02459236 |
| placebo | DRUG | Phase PHASE2 | Chronic Refractory Cough | COMPLETED | NCT01703923 |
| FP01 | DRUG | Phase PHASE2 | Chronic Refractory Cough | COMPLETED | NCT01703923 |